Logo
x

Search

Subscribe Now

Eli Lilly

Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events

Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events

  • November 19, 2024
Eli Lilly Reports the MHRA’s Approval of Kisunla (Donanemab) to Treat Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

Eli Lilly Reports the MHRA’s Approval of Kisunla (Donanemab) to Treat Mild Cognitive Impairment and Mild Dementia Due to Alzheimer...

  • October 23, 2024
Eli Lilly Highlights 1 Year Analysis from the P-III (VIVID-1) Trial of Mirikizumab for Treating Crohn's Disease at UEG Week 2024

Eli Lilly Highlights 1 Year Analysis from the P-III (VIVID-1) Trial of Mirikizumab for Treating Crohn's Disease at UEG Week 2024

  • October 15, 2024
PharmaShots' Key Highlights of Third Quarter 2024

PharmaShots' Key Highlights of Third Quarter 2024

  • October 1, 2024
Eli Lilly's Kisunla (Donanemab-azbt) Receives the MHLW’s Approval for Treating Early Symptomatic Alzheimer's Disease (AD)

Eli Lilly's Kisunla (Donanemab-azbt) Receives the MHLW’s Approval for Treating Early Symptomatic Alzheimer's Disease (AD)

  • September 25, 2024
Eli Lilly’s Ebglyss (L ebrikizumab-lbkz) Receives the US FDA’s Approval for Treating Moderate-to-Severe Atopic Dermatitis

Eli Lilly’s Ebglyss (L ebrikizumab-lbkz) Receives the US FDA’s Approval for Treating Moderate-to-Severe Atopic Dermatitis

  • September 16, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.